EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Gene-Silencing Therapeutic Approaches Targeting PI3K/Akt/mTOR Signaling in Degenerative Intervertebral Disk Cells: An In Vitro Comparative Study Between RNA Interference and CRISPR–Cas9

Masao Ryu iD, Takashi Yurube iD, Yoshiki Takeoka iD, Yutaro Kanda iD, Takeru Tsujimoto iD, Kunihiko Miyazaki iD, Hiroki Ohnishi iD, Tomoya Matsuo iD, Naotoshi Kumagai iD, Kohei Kuroshima iD, Yoshiaki Hiranaka iD, Ryosuke Kuroda und 1 weitere

Cells · 2024

DOI: 10.3390/cells13232030 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cells, 2024. Verfasst von Masao Ryu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mammalian target of rapamycin (mTOR), a serine/threonine kinase, promotes cell growth and inhibits autophagy. The following two complexes contain mTOR: mTORC1 with the regulatory associated protein of mTOR (RAPTOR) and mTORC2 with the rapamycin-insensitive companion of mTOR (RICTOR). The phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR signaling pathway is important in the intervertebral disk, which is the largest avascular, hypoxic, low-nutrient organ in the body. To examine gene-silencing therapeutic approaches targeting PI3K/Akt/mTOR signaling in degenerative disk cells, an in vitro comparative study was designed between small interfering RNA (siRNA)-mediated RNA interference (RNAi) and clustered regularly interspaced short palindromic repeat (CRISPR)–CRISPR-associated protein 9 (Cas9) gene editing. Surgically obtained human disk nucleus pulposus cells were transfected with a siRNA or CRISPR–Cas9 plasmid targeting mTOR, RAPTOR, or RICTOR. Both of the approaches specifically suppressed target protein expression; however, the 24-h transfection efficiency differed by 53.8–60.3% for RNAi and 88.1–89.3% for CRISPR–Cas9 (p < 0.0001). Targeting mTOR, RAPTOR, and RICTOR all induced autophagy and inhibited apoptosis, senescence, pyroptosis, and matrix catabolism, with the most prominent effects observed with RAPTOR CRISPR–Cas9. In the time-course analysis, the 168-h suppression ratio of RAPTOR protein expression was 83.2% by CRISPR–Cas9 but only 8.8% by RNAi. While RNAi facilitates transient gene knockdown, CRISPR–Cas9 provides extensive gene knockout. Our findings suggest that RAPTOR/mTORC1 is a potential therapeutic target for degenerative disk disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktSignal TransductionRNA InterferenceIntervertebral Disc DegenerationHumansGene SilencingPhosphatidylinositol 3-KinasesNucleus PulposusIntervertebral DiscAutophagyRegulatory-Associated Protein of mTORRNA, Small InterferingMaleFemaleMiddle Aged

Stichwörter der Autor:innen

RNA interference (RNAi)autophagyclustered regularly interspaced short palindromic repeat (CRISPR)–CRISPR-associ…disk degenerationgene-silencing therapyintervertebral disknucleus pulposus (NP) cellsphosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) s…small interfering RNA (siRNA)spine

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesRegulatory-Associated Protein of mTORRNA, Small InterferingMTOR protein, human

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

ORCID-Profile: Masao Ryu, Takashi Yurube, Yoshiki Takeoka, Yutaro Kanda, Takeru Tsujimoto, Kunihiko Miyazaki, Hiroki Ohnishi, Tomoya Matsuo, Naotoshi Kumagai, Kohei Kuroshima, Yoshiaki Hiranaka, Kenichiro Kakutani

Förderung

  • Japan Society for the Promotion of Science
  • JSPS KAKENHI

Zitieren

APA

Ryu, M., Yurube, T., Takeoka, Y., Kanda, Y., Tsujimoto, T., Miyazaki, K., Ohnishi, H., Matsuo, T., Kumagai, N., Kuroshima, K., Hiranaka, Y., Kuroda, R., & Kakutani, K. (2024). Gene-Silencing Therapeutic Approaches Targeting PI3K/Akt/mTOR Signaling in Degenerative Intervertebral Disk Cells: An In Vitro Comparative Study Between RNA Interference and CRISPR–Cas9. Cells. https://doi.org/10.3390/cells13232030

Vancouver

Ryu M, Yurube T, Takeoka Y, Kanda Y, Tsujimoto T, Miyazaki K, et al. Gene-Silencing Therapeutic Approaches Targeting PI3K/Akt/mTOR Signaling in Degenerative Intervertebral Disk Cells: An In Vitro Comparative Study Between RNA Interference and CRISPR–Cas9. Cells. 2024. doi:10.3390/cells13232030

BibTeX
@article{Ryu2024,
  author = {Ryu, Masao and Yurube, Takashi and Takeoka, Yoshiki and Kanda, Yutaro and Tsujimoto, Takeru and Miyazaki, Kunihiko and Ohnishi, Hiroki and Matsuo, Tomoya and Kumagai, Naotoshi and Kuroshima, Kohei and Hiranaka, Yoshiaki and Kuroda, Ryosuke and Kakutani, Kenichiro},
  title = {Gene-Silencing Therapeutic Approaches Targeting PI3K/Akt/mTOR Signaling in Degenerative Intervertebral Disk Cells: An In Vitro Comparative Study Between RNA Interference and CRISPR–Cas9},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13232030}
}
Kostenlos starten →